Padler-Karavani Vered
Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv 69978, Israel.
Cell Chem Biol. 2016 Dec 22;23(12):1446-1447. doi: 10.1016/j.chembiol.2016.12.002.
Advances in genomics and bioinformatics facilitated identification of tumor-specific neoantigens as optimal targets for cancer immunotherapy. In this hot topic, most efforts focus on mutant peptide antigens, overlooking tumor-associated glycosylation changes. Given the latest progress in glycomics, in this issue of Cell Chemical Biology, Xia et al. (2016) use glyco-antigen microarrays to investigate immune responses to whole cancer vaccines and provide important insights into vaccine efficacy.
基因组学和生物信息学的进展促进了肿瘤特异性新抗原作为癌症免疫治疗最佳靶点的鉴定。在这个热门话题中，大多数研究都集中在突变肽抗原上，而忽略了肿瘤相关的糖基化变化。鉴于糖组学的最新进展，在本期《细胞化学生物学》中，夏等人（2016年）使用糖抗原微阵列来研究对全癌疫苗的免疫反应，并为疫苗疗效提供了重要见解。
